ArticleTherapeutic advances in medical oncology2020
Clinical outcomes of patients with
Article in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis.British journal of clinical pharmacology · 2022Pooled it
- Trastuzumab Deruxtecan in Patients WithJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023Trial
- Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).BMC medicine · 2022Trial
- Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/MetastaticJCO precision oncology · 2026Observational
- Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France.Cancer medicine · 2026Observational
- Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials.JAMA network open · 2025Observational
- Optimization of First-Line Treatment Options in HER2-Altered Lung Adenocarcinoma: A Real-World Study.Cancer medicine · 2025Article
- Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations.Journal of translational medicine · 2025Review
- Revisiting HER2 in Prostate Cancer from an Inclusive Perspective: From Biomarkers to Omics.Cancers · 2024Review
- A retrospective study of first-line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations.Cancer medicine · 2024Article
- Dacomitinib exhibits promising activity against the rareHeliyon · 2024Article
- Prevalence and treatment of human epidermal growth factor receptor 2-altered non-small cell lung cancer: a retrospective analysis and systematic literature review.Ecancermedicalscience · 2024Article
- Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations.Journal of cancer research and clinical oncology · 2023Article
- Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis.Translational lung cancer research · 2023Article
- [Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing.Cancer research and treatment · 2023Article
- Review
- Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.Nature cancer · 2022Article
- HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is now the leading cause of cancer mortality worldwide for both men and women. In non-small cell lung cancer (NSCLC), matching a specifically targeted drug to the identified driver mutation in each patient resulted in dramatically improved therapeutic efficacy, often in conjunction with decreased toxicity. Mutations in
methodsPatients who were diagnosed with advanced lung cancer (stage IIIB/IV) and had undergone molecular testing at Zhongshan Hospital, Fudan University, Shanghai, China from April 2016 to December 2018 were reviewed. For patients that had
resultsWe identified 44 patients harboring
conclusionPemetrexed-based chemotherapy remains an important component of care for patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.